PT Diagnos Laboratorium Utama Tbk (IDX:DGNS)
Indonesia · Delayed Price · Currency is IDR 296.00
+14.00 (4.96%)
Nov 5, 2026, 3:40 PM WIB
IDX:DGNS Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 180,752 | 166,624 | 163,072 | 145,696 | 192,886 | 302,182 | |
Revenue Growth | 14.41% | 2.18% | 11.93% | -24.46% | -36.17% | 64.97% |
Cost of Revenue | 96,284 | 88,341 | 90,998 | 86,384 | 99,127 | 153,626 |
Gross Profit | 84,468 | 78,283 | 72,074 | 59,312 | 93,759 | 148,555 |
Selling, General & Admin | 79,367 | 72,984 | 70,113 | 73,420 | 78,320 | 67,127 |
Other Operating Expenses | 2,115 | -829.79 | 36.37 | 1,043 | -1,660 | - |
Operating Expenses | 81,482 | 72,154 | 70,150 | 74,463 | 76,660 | 67,127 |
Operating Income | 2,986 | 6,129 | 1,924 | -15,151 | 17,099 | 81,429 |
Interest Expense | -590.73 | -775.6 | -881.83 | -475.24 | -628.02 | -331.52 |
Interest & Investment Income | 7.8 | 53.92 | 107.37 | 392.24 | 862.94 | 2,217 |
Other Non Operating Income (Expenses) | - | - | 0 | - | - | -35.1 |
EBT Excluding Unusual Items | 2,403 | 5,407 | 1,150 | -15,234 | 17,333 | 83,279 |
Gain (Loss) on Sale of Assets | - | -0.83 | -285.77 | 1,661 | - | - |
Pretax Income | 2,403 | 5,406 | 863.77 | -13,573 | 17,333 | 83,279 |
Income Tax Expense | 1,282 | 2,469 | 116.32 | 83 | 4,669 | 18,975 |
Net Income | 1,121 | 2,937 | 747.44 | -13,656 | 12,665 | 64,304 |
Net Income to Common | 1,121 | 2,937 | 747.44 | -13,656 | 12,665 | 64,304 |
Net Income Growth | - | 292.95% | - | - | -80.31% | 22.05% |
Shares Outstanding (Basic) | 1,292 | 1,250 | 1,250 | 1,250 | 1,250 | 1,240 |
Shares Outstanding (Diluted) | 1,292 | 1,250 | 1,250 | 1,250 | 1,250 | 1,240 |
Shares Change | 3.36% | - | - | - | 0.78% | 24.04% |
EPS (Basic) | 0.87 | 2.35 | 0.60 | -10.92 | 10.13 | 51.84 |
EPS (Diluted) | 0.87 | 2.35 | 0.60 | -10.92 | 10.00 | 51.84 |
EPS Growth | - | 292.95% | - | - | -80.71% | -1.60% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -499.26 | 2,585 | -16,095 | -25,141 | -40,052 | -8,966 |
Free Cash Flow Per Share | -0.39 | 2.07 | -12.88 | -20.11 | -32.04 | -7.23 |
Gross Margin | 46.73% | 46.98% | 44.20% | 40.71% | 48.61% | 49.16% |
Operating Margin | 1.65% | 3.68% | 1.18% | -10.40% | 8.87% | 26.95% |
Profit Margin | 0.62% | 1.76% | 0.46% | -9.37% | 6.57% | 21.28% |
Free Cash Flow Margin | -0.28% | 1.55% | -9.87% | -17.26% | -20.77% | -2.97% |
EBITDA | 12,093 | 14,911 | 13,688 | -3,604 | 26,494 | 86,244 |
EBITDA Margin | 6.69% | 8.95% | 8.39% | -2.47% | 13.74% | 28.54% |
D&A For EBITDA | 9,107 | 8,782 | 11,764 | 11,547 | 9,396 | 4,815 |
EBIT | 2,986 | 6,129 | 1,924 | -15,151 | 17,099 | 81,429 |
EBIT Margin | 1.65% | 3.68% | 1.18% | -10.40% | 8.87% | 26.95% |
Effective Tax Rate | 53.35% | 45.67% | 13.47% | - | 26.93% | 22.79% |
Advertising Expenses | - | 6,353 | 6,578 | 6,159 | 7,007 | 5,078 |